11 completed, 4 unknown, 3 enrolling by invitation, 1 active not recruiting. 6 Phase 3, 5 Phase 2, 4 Not applicable, 3 Phase 1, 1 Phase 4.
Follow Primary Breast Cancer: new trials by email Literature Review of Primary Breast Cancer trials Research Report on Primary Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Molecular Imaging of EpCam Expression in Breast Cancer Using [99mTc]Tc-DARPinEc1-G3C [99mTc]Tc-DARPinEc1-G3C - Primary Breast Cancer | Phase 1 | Enrolling by invitation | Tomsk National Research Medical Center of the Russian Academy of Sciences | 10 | 2026-06-22 | 2026-08-26 |
| Large Language Model-Based Emotional Management for Breast Cancer Patients Large Language Model-Based precision emotional intervention system, Usual Care Group - Primary Breast Cancer | Not applicable | Active not recruiting | Nanfang Hospital, Southern Medical University | 440 | 2026-03-24 | 2026-09-22 |
| Evaluation of Different Types of HER2 Expression in Breast Cancer Using [99mTc]Tc -ZHER2:4107 Injection of [99mTc]Tc-ZHER2:4107, SPECT/CT - Primary Breast Cancer | Phase 2 | Enrolling by invitation | Tomsk National Research Medical Center of the Russian Academy of Sciences | 50 | 2025-10-20 | 2026-06-24 |
| [99mTc]Tc-DB8 Accumulation in Primary Tumor in Breast Cancer With Positive and Negative Estrogen Receptor Expression [99mTc]Tc-DB8 - Primary Breast Cancer | Phase 2 | Enrolling by invitation | Tomsk National Research Medical Center of the Russian Academy of Sciences | 40 | 2025-10-01 | 2026-06-24 |
| ADIE-BC - Aligning Dimensions of Interoceptive Experience in Breast Cancer Survivors Interoceptive training - Cancer, Primary Breast Cancer | Not applicable | Completed | King's College London | 21 | 2025-06-13 | 2026-04-23 |
| Molecular Imaging of HER2 Expression in Breast Cancer Using [123I] I-(HE)3-G3 SPECT - Primary Breast Cancer | Phase 1 | Completed | Tomsk National Research Medical Center of the Russian Academy of Sciences | 10 | 2023-09-01 | 2026-06-24 |
| mULM to Support Breast Cancer Diagnosis and Therapy Application and measurement of tumor vascularization using diagnostic contrast enhanced ultrasound (CEUS) - Primary Breast Cancer | Not applicable | Unknown | RWTH Aachen University | 74 | 2021-04-26 | 2023-11-18 |
| Clip Marker Placement in Primary Lesions of Breast Cancer Patients Receiving Neoadjuvant Therapy Tumark® Vision clip - Primary Breast Cancer | Completed | Kliniken Essen-Mitte | 339 | 2020-05-14 | 2023-11-24 | |
| Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3 SPECT - Primary Breast Cancer | Phase 1 | Completed | Tomsk National Research Medical Center of the Russian Academy of Sciences | 30 | 2020-02-10 | 2026-06-24 |
| Comparative Study of Scalp Cooling System and Chemical Cold Cap (COHAIR Study) Scalp cooling system, Cold cap - Primary Breast Cancer | Phase 3 | Unknown | Tao OUYANG | 256 | 2019-03-07 | 2021-11-29 |
| Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy Vinorelbine - Primary Breast Cancer | Phase 4 | Unknown | Tao OUYANG | 304 | 2017-11-10 | 2020-10-28 |
| Breast Cancer Proteomics and Molecular Heterogeneity Primary Breast Cancer, Recurrent/Metastatic Breast Cancer | Recruiting | Cancer Trials Ireland | 1780 | 2013-02-01 | 2025-12-19 | |
| Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE) Cabacitaxel, Paclitaxel - Primary Breast Cancer | Phase 2 | Completed | GBG Forschungs GmbH | 333 | 2013-02-01 | 2017-08-01 |
| Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy paclitaxel/anthracycline - Primary Breast Cancer | Phase 3 | Unknown | Tao OUYANG | 400 | 2011-03-04 | 2021-11-29 |
| Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy Docetaxel Cyclophosphamide, Cyclophosphamide Fluorouracil Epirubicin Docetaxel, Epirubicin Cyclophosphamide Paclitaxel - Primary Breast Cancer | Phase 3 | Completed | Fudan University | 1570 | 2010-06-01 | 2020-05-19 |
| Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER) Paclitaxel, Docetaxel, Cyclophosphamide - Primary Breast Cancer | Phase 3 | Completed | Fudan University | 2079 | 2010-06-01 | 2020-02-26 |
| Effectiveness of the CHESS eHealth Cancer Support Intervention in Population-based Care Enhanced ICCS with KPNW web resources and the Comprehensive Health Enhancement Support System (CHESS.) - Primary Breast Cancer | Not applicable | Completed | University of Wisconsin, Madison | 368 | 2009-11-01 | 2019-11-18 |
| Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer Epirubicin, Cyclophosphamide, Docetaxel - Primary Breast Cancer, Her2 Non-overexpressing | Phase 3 | Completed | Women's Cancer Study Group GmbH | 3198 | 2009-02-05 | 2019-08-14 |
| Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel Epirubicin, Carboplatin, Docetaxel - Primary Breast Cancer | Phase 2 | Completed | Klinikum Weissenfels | 50 | 2006-05-01 | 2010-01-15 |
| Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow Zoledronic acid + Calcium/Vitamin D - Primary Breast Cancer | Phase 2 | Terminated | Novartis Pharmaceuticals | 96 | 2002-01-01 | 2009-12-23 |
Showing 20 of 21. Sign in to see all of them.
Breast Neoplasms (9) · Alopecia (1) · Emotional Regulation (1) · Neoplasm, Residual (1) · Neoplasms (1)
Skin Diseases (10) · Skin and Connective Tissue Diseases (10) · Breast Diseases (9) · Neoplasms (9) · Neoplasms by Site (9) · Pathological Conditions, Signs and Symptoms (2) · Behavior (1) · Hair Diseases (1) · Hypotrichosis (1) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Anatomical (1) · Self-Control (1) · Social Behavior (1)
Docetaxel (4) · Cyclophosphamide (3) · Epirubicin (3) · Paclitaxel (3) · Anthracyclines (1) · CP protocol (1) · Calcium (1) · Carboplatin (1) · Doxorubicin (1) · Fluorouracil (1) · Iodine-123 (1) · Tamoxifen (1) · Vinorelbine (1) · Vitamin D (1) · Zoledronic Acid (1)
Tomsk National Research Medical Center of the Russian Academy of Sciences (5) · Tao OUYANG (3) · Fudan University (2) · GBG Forschungs GmbH (2) · Cancer Trials Ireland (1) · King's College London (1) · Kliniken Essen-Mitte (1) · Klinikum Weissenfels (1) · Nanfang Hospital, Southern Medical University (1) · Novartis Pharmaceuticals (1) · RWTH Aachen University (1) · University of Wisconsin, Madison (1) · Women's Cancer Study Group GmbH (1)
Germany (7) · China (5) · Russia (5) · Ireland (1) · United Kingdom (1) · United States (1)
Vladimir I Chernov, MD, Prof (2) · Dieter Lampe, Dr. med. (1) · Elmar Stickeler, Prof Dr. med (1) · Gunter von Minckwitz, Prof. Dr. (1) · Lauren C. Heathcote, PhD (1) · Mattea Reinisch, MD (1) · Nadia Harbeck, Prof. Dr. med. (1) · Olga Bragina, Dsc (1) · Sherko Kuemmel, MD, PhD (1) · Tao Ouyang, Doctor (1) · Timothy Baker (1) · Ulrike A. Nitz, Prof. Dr. med. (1) · Vladimir I Chernov (1)
PMID 15837982, PMID 16983592, PMID 19758440, PMID 22508812, PMID 24128322, PMID 26926676, PMID 28399921, PMID 28664507, PMID 28768217, PMID 30785826, PMID 32408905, PMID 33208158, PMID 34385343, PMID 38852945, PMID 38979716, PMID 39604957, PMID 41066509, PMID 41955993
P50CA095817 (1)